CorNeat Vision leverages synthetic biology to introduce implants that address unresolved ophthalmic challenges in the areas of corneal blindness, ocular trauma, glaucoma, hypotony and epiphora (tearing). Our overarching mission is to promote human health, sustainability and equality worldwide with an initial focus on addressing global corneal blindness.
Our permanent ophthalmic implants utilize advanced cell technology and nanoscale chemical engineering to mimic cellular and subcellular structures, stimulating cellular growth and complete integration with surrounding tissue.
We couple innovative ideas and tissue integration capability to fabricate solutions, which serve to replace damaged biological organs and tissue and repair their function.
We aim to improve the lives of affected people by offering innovative, permanent, convenient and affordable solutions by leveraging our unique technology and R&D capabilities. We have successfully developed an artificial cornea (the CorNeat KPro) and an artificial sclera (the CorNeat EverPatch), which will improve the quality of life for many in need. Our first two products have successfully passed all pre-clinical requirements and will enter the clinical phase in 2019.
While our first devices enter the clinical phase, R&D and financial resources are focused on new applications, which will significantly expand the ophthalmic indications we target and evaluate the use of associated technology in additional fields.
We constantly work on developing new products based on our unique technology, creating a pipeline for the future
CorNeat Vision is an ophthalmic medical device company with an overarching mission of promoting human health, sustainability and equality worldwide. CorNeat Vision produces a lineup of innovative, safe, affordable and long-lasting ophthalmic medical solutions, including the CorNeat KPro and the CorNeat EverPatch. Our products will significantly impact ophthalmic surgery practices in the areas of cornea, sclera, glaucoma (trabecular mesh), myopia and more. We are working relentlessly to significantly improve the well-being, quality of life, and general independence of blind and visually-impaired patients by developing synthetic products, which replace the damaged organ or revert disease processes leading to impaired vision and/or blindness.